German China

USA: Cell Biology Cell Therapy for Parkinson’s Disease Ready for Clinical Trials

Editor: Alexander Stark

A new study has focused on developing stem cell-derived midbrain dopamine progenitors for the treatment of Parkinson’s Disease. It cites how Amsbio's Stem-Cellbanker animal-free cryopreservation media has played a role in the development. The therapy will soon be going into clinical trials.

Related Company

A pioneering study has focused on developing stem cell-derived midbrain dopamine progenitors for the treatment of Parkinson’s Disease.
A pioneering study has focused on developing stem cell-derived midbrain dopamine progenitors for the treatment of Parkinson’s Disease.
(Source: Public Domain / Pixabay )

New York/USA — Parkinson’s disease is one of the most common neurodegenerative diseases worldwide. Its main features include motor symptoms such as bradykinesia, rigidity, resting tremor, and postural instability, though non-motor symptoms are often also present. Currently the main therapy for Parkinson's disease consists of augmentation of dopamine levels in the brain via dopamine supplements or agonists or by inhibiting dopamine degradation. Treatment using this methodology is symptomatic but not long-lasting, and unfortunately has no neuroprotective effect. Cell therapy with grafts of human fetal tissue from the ventral mesencephalon have been carried out successfully, with multiple reports of long-term benefits.

A pioneering study from the Centre for Stem Cell Biology at the Memorial Sloan Kettering Cancer Centre (USA) has focused on developing stem cell-derived midbrain dopamine progenitors for the treatment of Parkinson’s Disease. This study highlighted, amongst other things, that scientists have been able to demonstrate the efficacy of Stem-Cellbanker to store, thaw and then recover these manufactured cells for clinical use in patients.

Stem-Cellbanker is a ready-to-use, chemically defined, animal-free freezing medium manufactured under GMP conditions. It is optimized for embryonic stem (ES) and induced pluripotent stem (iPS) cell storage, as well as being a suitable solution for the cryopreservation of other fragile cell types. Containing only European or US Pharmacopoeia graded ingredients, the medium is designed for storage of cells developed for cell therapy applications. It is also available as a DMSO free formulation. According to the company, the medium significantly increases cell viability while maintaining cell pluripotency, normal karyotype and proliferation ability after freeze-thaw. The product is ready-to-use and requires no special devices, such as a controlled rate freezer, in order to achieve consistently high viabilities following resuscitation from cryopreservation, even over extended long-term storage.

(ID:47437112)